Correction in vitro of lymphocyte activation defect in autoimmune mice.
D000375:Aging; D000818:Animals; D001327:Autoimmune Diseases / Q000235:genetics / Q000276:immunology*; D000001:Calcimycin / Q000494:pharmacology; D003208:Concanavalin A / Q000494:pharmacology; D004247:DNA / Q000096:biosynthesis; D005786:Gene Expression Regulation; D007376:Interleukin-2 / Q000235:genetics / Q000502:physiology*; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D051379:Mice; D011519:Proto-Oncogenes; D011971:Receptors, Immunologic / Q000096:biosynthesis / Q000235:genetics; D015375:Receptors, Interleukin-2; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D007376:Interleukin-2; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2; D003208:Concanavalin A; D000001:Calcimycin; D004247:DNA; D013755:Tetradecanoylphorbol Acetate